BLTE — Belite Bio Income Statement
0.000.00%
Last trade - 00:00- $1.85bn
- $1.71bn
- 32
- 22
- 82
- 42
Annual income statement for Belite Bio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 20-F | 20-F | 20-F |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 5.74 | 9.8 | 12.8 | 31.7 | 40 |
| Operating Profit | -5.74 | -9.8 | -12.8 | -31.7 | -40 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -5.75 | -9.67 | -12.6 | -31.6 | -36.1 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -5.75 | -9.67 | -12.6 | -31.6 | -36.1 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -5.75 | -9.67 | -12.6 | -31.6 | -36.1 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -5.75 | -9.67 | -12.6 | -31.6 | -36.1 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.239 | -0.401 | -0.633 | -1.19 | -1.18 |